Novo Nordisk A/S
NOVO-B
Rang in aandelen
#105
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Aandeelprijs
$39.75
Marktkapitalisatie
$175.44B
Verandering (1 dag)
1.32%
Verandering (1 jaar)
-25.55%
Land
DK
Handel Novo Nordisk A/S (NOVO-B)
Categorie
Healthcare
P/B-ratio voor Novo Nordisk A/S (NOVO-B)
P/B-ratio op February 2026 TTM: 7.11
Volgens de meest recente financiële rapporten en aandelenkoers van Novo Nordisk A/S is de huidige P/B-ratio (TTM) 7.11. Eind 2024 had het bedrijf een P/B-ratio van 19.38.
P/B-ratiohistoriek voor Novo Nordisk A/S van 2001 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 7.11 | -4.53% |
| 2025 | 7.45 | -61.56% |
| 2024 | 19.38 | -34.02% |
| 2023 | 29.37 | 15.39% |
| 2022 | 25.45 | 6.65% |
| 2021 | 23.87 | 51.77% |
| 2020 | 15.72 | -1.35% |
| 2019 | 15.94 | 12.22% |
| 2018 | 14.20 | -14.34% |
| 2017 | 16.58 | 16.48% |
| 2016 | 14.23 | -34.97% |
| 2015 | 21.89 | 29.23% |
| 2014 | 16.94 | 35.36% |
| 2013 | 12.51 | -0.67% |
| 2012 | 12.60 | 26.42% |
| 2011 | 9.97 | 0.88% |
| 2010 | 9.88 | 77.44% |
| 2009 | 5.57 | 9.91% |
| 2008 | 5.07 | -20.41% |
| 2007 | 6.36 | 25.26% |
| 2006 | 5.08 | 20.40% |
| 2005 | 4.22 | 11.39% |
| 2004 | 3.79 | 16.59% |
| 2003 | 3.25 | 4.96% |
| 2002 | 3.10 | -47.14% |
| 2001 | 5.86 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 34.4295 | 384.06% |
US
|
|
| 7.8748 | 10.72% |
US
|
|
| -84.9599 | -1,294.50% |
US
|
|
| 9.0001 | 26.54% |
US
|
|
| 8.4776 | 19.19% |
CH
|
